




“Point in Time” Act Content
OPIOID DAMAGES AND HEALTH CARE COSTS RECOVERY ACT
[SBC 2018] CHAPTER 35






NOTE:

Links below go to act content as it was prior to the changes
made on the effective date. (PIT covers changes made from
September 6, 2000 to "current to" date of the act.)




SECTION
EFFECTIVE DATE


1

November 3, 2022





November 3, 2022





November 3, 2022





November 3, 2022



2

November 3, 2022



2.1

November 3, 2022



3

November 3, 2022



4

November 3, 2022





November 3, 2022





November 3, 2022



5

November 3, 2022



6

November 3, 2022



7

November 3, 2022





November 3, 2022



7.1

November 3, 2022



10

November 3, 2022



Schedule

November 3, 2022









Section 1 (1) definitions of "active ingredient" and "consultant"
were added by 2022-34-1(a), effective November 3, 2022 (Royal
Assent).





Section 1 (1) definitions of "cost of health care benefits", "health
care benefits", "manufacturer", "opioid product" and "opioid-related
wrong" BEFORE amended by 2022-34-1(b) to (f), effective November 3,
2022 (Royal Assent).



"cost of health care benefits"

means the sum of




(a)

the present value of the total expenditure by the government for
health care benefits provided for insured persons as a result of
opioid-related disease, injury or illness or the risk of
opioid-related disease, injury or illness, and




(b)

the present value of the estimated total expenditure by the
government for health care benefits that could reasonably be
expected to be provided for those insured persons as a result of
opioid-related disease, injury or illness or the risk of
opioid-related disease, injury or illness;



"health care benefits"

means




(a)

benefits as defined under the
Hospital Insurance Act
,




(b)

benefits as defined under the
Laboratory Services Act
,




(c)

benefits as defined under the
Medicare Protection Act
,




(d)

benefits as defined under the
Pharmaceutical Services Act
,




(e)

payments made by the government under the
Continuing Care Act
, and




(f)

other expenditures by the government, made directly or through one
or more agents or other intermediate bodies, for programs, services,
benefits or similar matters associated with disease, injury or
illness;



"manufacturer"

means a person who manufactures or has manufactured an opioid
product and a person who, in the past or currently,




(a)

causes, directly or indirectly, through arrangements with
contractors, subcontractors, licensees, franchisees or others, the
manufacture of an opioid product,




(b)

for any fiscal year of the person, derives at least 10% of revenues,
determined on a consolidated basis in accordance with generally
accepted accounting principles in Canada, from the manufacture or
promotion of opioid products by that person or by other persons,




(c)

engages in or causes, directly or indirectly, other persons to
engage in promoting an opioid product, or




(d)

is a trade association primarily engaged in




(i)

advancing the interests of manufacturers,




(ii)

promoting an opioid product, or




(iii)

causing, directly or indirectly, other persons to engage in
promoting an opioid product;



"opioid product"

means any product that contains




(a)

a drug set out in the Schedule, or




(b)

a drug prescribed by regulation;



"opioid-related wrong"

means




(a)

a tort that is committed in British Columbia by a manufacturer or
wholesaler and that causes or contributes to opioid-related disease,
injury or illness, or




(b)

in an action under section 2 (1), a breach, by a manufacturer or
wholesaler, of a common law, equitable or statutory duty or
obligation owed to persons in British Columbia who have used or been
exposed to or might use or be exposed to an opioid product;





Section 1 (6) BEFORE amended by 2022-34-1(g), effective November 3,
2022 (Royal Assent).




(6)

For the purposes of determining the market share of a defendant for
a type of opioid product sold in British Columbia, the court must
calculate the defendant's market share for the type of opioid
product by the following formula:




dms =
dm
× 100%







MM







where


dms
=

the defendant's market share for the type of opioid product
from the date of the earliest opioid-related wrong committed
by that defendant to the date of trial;



dm
=

the quantity of the type of opioid product manufactured or
promoted by the defendant that is distributed or sold within
British Columbia from the date of the earliest opioid-related
wrong committed by that defendant to the date of trial;



MM
=

the quantity of the type of opioid product manufactured or
promoted by all manufacturers or wholesalers that is purchased
or dispensed within British Columbia for the purpose of
providing health care benefits from the date of the earliest
opioid-related wrong committed by the defendant to the date of
trial.








Section 1 (7) was added by 2022-34-1(h), effective November 3, 2022
(Royal Assent).





Section 2 (1) BEFORE amended by 2022-34-2, effective November 3,
2022 (Royal Assent).




(1)

The government has a direct and distinct action against a
manufacturer or wholesaler to recover the cost of health care
benefits caused or contributed to by an opioid-related wrong.





Section 2.1 was enacted by 2022-34-3, effective November 3, 2022
(Royal Assent).





Section 3 (1) (part) BEFORE amended by 2022-34-4 and 5, effective
November 3, 2022 (Royal Assent).




(1)

In an action under section 2 (1) for the recovery of the cost of
health care benefits on an aggregate basis, subsection (2) of this
section applies if the government proves, on a balance of
probabilities, that, in respect of a type of opioid product,





Section 4 (1) BEFORE amended by 2022-34-4, effective November 3,
2022 (Royal Assent).




(1)

Two or more defendants in an action under section 2 (1) are jointly
and severally liable for the cost of health care benefits if




(a)

those defendants jointly breached a duty or obligation described in
the definition of "opioid-related wrong" in section 1 (1), and




(b)

as a consequence of the breach described in paragraph (a) of this
subsection, at least one of those defendants is held liable in the
action under section 2 (1) for the cost of those health care
benefits.





Section 4 (2) (part) BEFORE amended by 2022-34-4 and 6, effective
November 3, 2022 (Royal Assent).




(2)

For purposes of an action under section 2 (1), 2 or more
manufacturers or wholesalers, whether or not they are defendants in
the action, are deemed to have jointly breached a duty or obligation
described in the definition of "opioid-related wrong" in section 1
(1) if





Section 4 (2) (a) and (b) (part) BEFORE amended by 2022-34-6,
effective November 3, 2022 (Royal Assent).




(a)

one or more of those manufacturers or wholesalers are held to have
breached the duty or obligation, and




(b)

at common law, in equity or under an enactment, those manufacturers
or wholesalers would be held





Section 5 (c) was added by 2022-34-7, effective November 3, 2022
(Royal Assent).





Section 6 BEFORE amended by 2022-34-8, effective November 3, 2022
(Royal Assent).





Limitation periods




6

(1)


No action that is commenced by the government within 2 years after
the coming into force of this section for the recovery of the cost
of health care benefits, or for damages, alleged to have been
caused or contributed to by an opioid-related wrong, is barred
under the
Limitation Act
.




(2)

Any action described in subsection (1) of this section for damages
alleged to have been caused or contributed to by an opioid-related
wrong is revived if the action was dismissed before the coming
into force of this section merely because it was held by a court
to be barred or extinguished by the
Limitation Act
.






Section 7 (2) (part) BEFORE amended by 2022-34-9, effective November
3, 2022 (Royal Assent).




(2)

If the government is unable to establish which defendant caused or
contributed to the use or exposure described in paragraph (b) and,
as a result of a breach of a common law, equitable or statutory duty
or obligation,





Section 7 (3) (e) BEFORE amended by 2022-34-6, effective November 3,
2022 (Royal Assent).




(e)

the degree to which a defendant collaborated or acted in concert
with other manufacturers or wholesalers in any conduct that caused,
contributed to or aggravated the risk of disease, injury or illness;





Section 7.1 was enacted by 2022-34-10, effective November 3, 2022
(Royal Assent).





Section 10 BEFORE amended by 2022-34-4, effective November 3, 2022
(Royal Assent).





Retroactive effect




10


A provision of this Act has the retroactive effect necessary to
give the provision full effect for all purposes, including
allowing an action to be brought under section 2 (1) arising from
an opioid-related wrong, whenever the opioid-related wrong
occurred.






Schedule, section 1 (part) and table heading BEFORE amended by
2022-34-11, effective November 3, 2022 (Royal Assent).






1


A product that contains any of the following drugs is an opioid
product for the purposes of this Act:






Drugs containing any of the following active ingredients



Including but not limited to









